Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 10, 2026 · Other material event · Financial statements
Humacyte, Inc.
65
Other material event
Jun 10, 2026
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
Humacyte, Inc. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients - Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012’s primary endpoi…
This filing reports Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Humacyte, Inc. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
